Navigating Upstream AAV Manufacturing Process Challenges in Next-Gen Bioprocessing
Adeno-associated virus (AAV) vectors have become the dominant delivery platform for gene therapies, with several FDA-approved products and many more in clinical trials. Yet upstream manufacturing remains a persistent bottleneck. Inconsistent cell line performance, variable transfection efficiency, and scale-up challenges create titer variability that lengthens time to clinic and increases costs.
Read more
